
Eli Lilly, maker of one of the blockbuster GLP-1 weight-loss drug Zepbound, says it will now offer the medication in single-dose vials at half the price currently available to consumers. The new 2.5 milligram (mg) and 5 mg weekly dose vials differ from the standard preloaded injector pens that are used to administer Zepbound (tirzepatide)… read on > read on >